These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 24328486)
61. CT imaging of pediatric patients with cystic fibrosis on ivacaftor therapy. Hayes D; Long FR; McCoy KS; Sheikh SI Lung; 2014 Oct; 192(5):823-4. PubMed ID: 25099273 [No Abstract] [Full Text] [Related]
62. Sweat chloride concentration in cystic fibrosis patients with cystic fibrosis trans-membrane conductance regulator 11234V mutation. Al-Mendalawi MD; Abdul-Wahab A; Janahi IA; Abdel-Rahman MO Saudi Med J; 2010 Mar; 31(3):339-40; author reply 340. PubMed ID: 20231949 [No Abstract] [Full Text] [Related]
63. Combination CFTR modulator therapy in children and adults with cystic fibrosis. Guimbellot JS; Taylor-Cousar JL Lancet Respir Med; 2021 Jul; 9(7):677-679. PubMed ID: 33965001 [No Abstract] [Full Text] [Related]
64. New cystic fibrosis drug paves the way for orphan diseases. Cooney D Lancet Respir Med; 2013 Apr; 1(2):104. PubMed ID: 24429084 [No Abstract] [Full Text] [Related]
66. Ivacaftor for patients with cystic fibrosis. Wainwright CE Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205 [TBL] [Abstract][Full Text] [Related]
67. The evidence for long-term benefits of restoration of CFTR function continues to grow. Boyle MP Am J Respir Crit Care Med; 2015 Oct; 192(7):774-6. PubMed ID: 26426780 [No Abstract] [Full Text] [Related]
68. Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels. Kopeikin Z; Yuksek Z; Yang HY; Bompadre SG J Cyst Fibros; 2014 Sep; 13(5):508-14. PubMed ID: 24796242 [TBL] [Abstract][Full Text] [Related]
69. [Therapeutic update in cystic fibrosis]. Durupt S; Nove Josserand R; Durieu I Rev Med Interne; 2014 Jun; 35(6):388-92. PubMed ID: 24309546 [TBL] [Abstract][Full Text] [Related]
70. Misdiagnosis of cystic fibrosis based on transient pancreatic insufficiency and elevated sweat chloride. Bagheri-Behrouzi A; Steiß JO; Zimmer KP; Nährlich L Klin Padiatr; 2015 Mar; 227(2):96-7. PubMed ID: 25751685 [No Abstract] [Full Text] [Related]
71. False dawn for cystic fibrosis disease modifiers? Holmes D Nat Rev Drug Discov; 2014 Oct; 13(10):713-4. PubMed ID: 25270946 [No Abstract] [Full Text] [Related]
72. Ivacaftor in a young boy with the rare gating mutation S549R--use of lung clearance index to track progress: a case report. Lenherr N; Lurà M; Trachsel D; Latzin P; Hammer J BMC Pulm Med; 2015 Oct; 15():123. PubMed ID: 26474553 [TBL] [Abstract][Full Text] [Related]
73. Hot off the breath: 'I've a cost for'--the 64 million dollar question. Bush A; Simmonds NJ Thorax; 2012 May; 67(5):382-4. PubMed ID: 22407889 [No Abstract] [Full Text] [Related]
74. Promising new era dawns for cystic fibrosis treatment. Corbyn Z Lancet; 2012 Apr; 379(9825):1475-6. PubMed ID: 22530244 [No Abstract] [Full Text] [Related]
75. Mutation-specific cystic fibrosis treatments on verge of approval. Dolgin E Nat Med; 2011 Apr; 17(4):396-7. PubMed ID: 21475213 [No Abstract] [Full Text] [Related]
76. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T. Carter S; Kelly S; Caples E; Grogan B; Doyle J; Gallagher CG; McKone EF J Cyst Fibros; 2015 Jul; 14(4):e4-5. PubMed ID: 25698453 [TBL] [Abstract][Full Text] [Related]